Asthma Disease Market Insight, Epidemiology, & Forecast (2024-2032F)
Emphasis on Marketed Therapies TEZSPIRE, TRELEGY ELLIPTA, ARNUITY ELLIPTA, CINQAIR (reslizumab), FASENRA, (benralizumab), DUPIXENT (dupilumab), NUCALA (mepolizumab), AIRSUPRA (albuterol and budesonide), and XOLAIR (omalizumab); Emerging Therapies GSK3511294, Givinostat, Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, PBF-680, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), and Atuliflapon (AZD5718) and Country
$3999 - $6999